Treatment typically commences with 0.25 mg weekly for four weeks (a non-therapeutic starter dose designed to improve gastrointestinal tolerability), followed by an increase to 0.5 mg weekly
11,14,17 Mortality A subset of the included studies provided extractable mortality data
A System-Based Review on Effects of Glucagon-Like Peptide-1 Receptor Agonists: Benefits vs Risks
Neurogastroenterol Motil 31:e13546 Camilleri M, Chedid V, Ford AC, Haruma K, Horowitz M, Jones KL et al (2018) Gastroparesis
As each method has its limitations, at least two carefully controlled approaches should be used to confirm a new cellular localization of the receptor
Once your body adjusts to a stable dose, many patients successfully reintroduce mild to moderate spice